Stingray Therapeutics

Stingray’s Vizenpistat (SR-8541A) is an oral first in class best innate immune checkpoint inhibitor, badly needed to help adaptive immune checkpoint inhibitors in the ½ of all tumors where they do not work. In 2 clinical trials, Vizenpistat has shown greater efficacy and high safety in clinical trials than competition.